Headlands Technologies LLC Has $604,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Headlands Technologies LLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 196.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,314 shares of the company's stock after purchasing an additional 59,211 shares during the period. Headlands Technologies LLC's holdings in Recursion Pharmaceuticals were worth $604,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $26,000. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC boosted its stake in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 220.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after purchasing an additional 6,758 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Remove Ads

Recursion Pharmaceuticals Stock Down 11.9 %

NASDAQ RXRX traded down $0.57 on Friday, reaching $4.24. The company had a trading volume of 28,071,567 shares, compared to its average volume of 11,038,431. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -2.77 and a beta of 1.00. The company's fifty day moving average is $7.22 and its 200-day moving average is $6.95. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.06 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the business earned ($0.42) earnings per share. Recursion Pharmaceuticals's revenue was down 57.8% compared to the same quarter last year. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

RXRX has been the subject of a number of recent analyst reports. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.